Skip to main content

Table 4 Cox regression result of the effect of adherence on survival

From: Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data

  One-year adherence to AET Three-year adherence to AET Five-year adherence to AET
Model HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Adherence 0.75 (0.61-0.92) <0.01 0.60 (0.44-0.83) <0.01 0.59 (0.34-1.01) 0.05
Adherence + Race 0.79 (0.64-0.97) <0.05 0.64 (0.46-0.89) <0.01 0.63 (0.36-1.07) 0.09
Adherence + Race+ Age 0.80 (0.65-0.98) <0.05 0.65 (0.47-0.90) <0.01 0.64 (0.37-1.10) 0.10
Adherence + Race+ Age+ Stage+ Comorbidity 0.84 (0.68-1.04) 0.12 0.65 (0.46-0.90) <0.01 0.58 (0.33-1.03) 0.06
Adherence + Race+ Age+ Stage+ Comorbidity+ SESa 0.85 (0.68-1.05) 0.13 0.62 (0.44-0.87) <0.01 0.55 (0.31-0.99) <0.05
Full modelb 0.87 (0.70-1.07) 0.19 0.66 (0.47-0.92) <0.05 0.54 (0.30-0.99) <0.05
  1. aSES variables include Poverty level, DPC physicians per 100 population, TX-Mexico border, Region
  2. bFull model includes model 5 plus chemotherapy, radiation therapy, surgery treatment or not and patient year of diagnosis
\